Jane L Liesveld

List of Publications by Year
in descending order

143 papers	4,848 citations	136950 32 h-index	106344 65 g-index
148 all docs	148 docs citations	148 times ranked	7460 citing authors

#	Article	IF	Citations
1	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood, 2022, 139, 1135-1146.	1.4	39
2	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	5.2	35
3	A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia. Leukemia Research, 2022, 112, 106749.	0.8	5
4	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	7.1	32
5	The therapeutic potential of bedside art observation in hematologic cancer inpatients: a randomized controlled pilot study. Supportive Care in Cancer, 2022, 30, 3585.	2.2	1
6	Cytopenia after CAR-T Cell Therapyâ€"A Brief Review of a Complex Problem. Cancers, 2022, 14, 1501.	3.7	43
7	Protocol for a pilot randomized controlled trial of a mobile health exercise intervention for older patients with myeloid neoplasms (GO-EXCAP 2). Journal of Geriatric Oncology, 2022, 13, 545-553.	1.0	2
8	Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists. Leukemia and Lymphoma, 2021, 62, 387-398.	1.3	20
9	Targeted therapy for treatment of patients with classical hairy cell leukemia. Leukemia Research, 2021, 102, 106522.	0.8	5
10	Developing and adapting a mobile health exercise intervention for older patients with myeloid neoplasms: A qualitative study. Journal of Geriatric Oncology, 2021, 12, 909-914.	1.0	10
11	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	2.4	6
12	Marrow failure and aging: The role of â€œInflammagingâ€• Best Practice and Research in Clinical Haematology, 2021, 34, 101283.	1.7	4
13	Reducing the Need for HLA-Matched Platelet Transfusion. New England Journal of Medicine, 2021, 384, 2451-2452.	27.0	15
14	Bone marrow failure syndromes. Best Practice and Research in Clinical Haematology, 2021, 34, 101288.	1.7	1
15	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
16	Interleukin-1/Toll-like Receptor Inhibition Can Restore the Disrupted Bone Marrow Microenvironment in Mouse Model of Myelodysplastic Syndromes. Blood, 2021, 138, 1510-1510.	1.4	2
17	Bone marrow mesenchymal stem cells from patients with SLE maintain an interferon signature during in vitro culture. Cytokine, 2020, 132, 154725.	3.2	9
18	Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support. Leukemia, 2020, 34, 391-403.	7.2	61

#	Article	IF	Citations
19	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
20	Comparison of outcomes of HCT in blast phase of BCR-ABL1â˜' MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757.	5.2	14
21	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leukemia and Lymphoma, 2020, 61, 2811-2820.	1.3	7
22	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
23	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, 2139-2146.	2.0	14
24	Autologous stem cell rescue recipient with neutrophil tissue delivery detected prior to blood engraftment: A case report. EJHaem, 2020, 1, 330-333.	1.0	2
25	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63
26	IFNÎ² signaling inhibits osteogenesis in human SLE bone marrow. Lupus, 2020, 29, 1040-1049.	1.6	8
27	Stem cell homing: From physiology to therapeutics. Stem Cells, 2020, 38, 1241-1253.	3.2	116
28	Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment. JAAD Case Reports, 2020, 6, 292-295.	0.8	8
29	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Advances, 2020, 4, 983-992.	5.2	34
30	Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. Biology of Blood and Marrow Transplantation, 2020, 26, 2335-2345.	2.0	28
31	Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans. Cell Reports Medicine, 2020, 1, 100015.	6.5	10
32	SY-1425, a Potent and Selective RARÎ± Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia. Blood, 2020, 136, 4-5.	1.4	10
33	A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 41-42.	1.4	6
34	Treatment Decision-Making and Decisional Support Experiences Among Acute Myeloid Leukemia Survivors. Blood, 2020, 136, 20-20.	1.4	1
35	Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARÎ± Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2020, 136, 6-7.	1.4	3
36	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML). Blood, 2020, 136, 41-42.	1.4	0

#	Article	IF	Citations
37	Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Blood, 2020, 136, 20-21.	1.4	1
38	Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia. Translational Oncology, 2019, 12, 602-613.	3.7	12
39	Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematology,the, 2019, 6, e122-e131.	4.6	20
40	Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes. Blood Reviews, 2019, 36, 57-69.	5.7	34
41	Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells. MBio, 2019, 10, .	4.1	24
42	CNS Melioidosis in a Traveler Returning from Cabo, Mexico. Open Forum Infectious Diseases, 2019, 6, ofz005.	0.9	4
43	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) Tj ETQq1 1 0.784314 rgBT /Ove methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematology,the, 2019, 6, e132-e143.	4.6	200
44	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Advances, 2019, 3, 670-680.	5.2	71
45	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biology of Blood and Marrow Transplantation, 2019, 25, 699-711.	2.0	11
46	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 362-368.	2.0	40
47	A Specific Mesenchymal Stem and Progenitor Cell (MSPC) Subpopulation with a Multi-Potent Gene Signature Is Transcriptionally Altered in the Setting of Myelodysplastic Syndrome (MDS) in Primary Human Bone Marrow Aspirates. Blood, 2019, 134, 1708-1708.	1.4	1
48	Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 1748-1753.	2.0	9
49	Can we incorporate geriatric assessment in the management of acute lymphoblastic leukemia in older adults?. Journal of Geriatric Oncology, 2018, 9, 296-301.	1.0	4
50	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplantation, 2018, 53, 535-555.	2.4	75
51	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biology of Blood and Marrow Transplantation, 2018, 24, 175-184.	2.0	7
52	Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. Leukemia and Lymphoma, 2018, 59, 1717-1721.	1.3	6
53	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 228-241.	2.0	43
54	Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. Blood Reviews, 2018, 32, 235-248.	5.7	48

#	Article	IF	Citations
55	Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. Cancers, 2018, 10, 179.	3.7	22
56	Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 2735-2735.	1.4	5
57	Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population. Blood, 2018, 132, 2245-2245.	1.4	1
58	Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 2246-2246.	1.4	4
59	Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses. Blood, 2018, 132, 331-331.	1.4	19
60	Novel mHealth App to Deliver Geriatric Assessment-Driven Interventions for Older Adults With Cancer: Pilot Feasibility and Usability Study. JMIR Cancer, 2018, 4, e10296.	2.4	55
61	Role of RasGRP3 in EPO/EPOR Signaling and Transmigration of Human Hematopoietic CD34+ Cells. Blood, 2018, 132, 4531-4531.	1.4	0
62	Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 145-151.	0.4	9
63	Bone Marrowâ€"Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescenceâ€Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Proteinâ€"Interferonâ€Î² Feedback Loop. Arthritis and Rheumatology, 2017, 69, 1623-1635.	5.6	56
64	ABO identical and washed blood transfusions as candidate strategies to reduce early mortality in acute promyelocytic leukemia. Leukemia Research, 2017, 62, 1-3.	0.8	10
65	Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies. Best Practice and Research in Clinical Haematology, 2017, 30, 184-192.	1.7	15
66	Improved outcomes in acute myeloid leukemia patients treated with washed transfusions. American Journal of Hematology, 2017, 92, E8-E9.	4.1	13
67	GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study. Blood, 2017, 130, 894-894.	1.4	9
68	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	4.1	45
69	Trouble in the niche? Send in a statin. Blood, 2016, 128, 2877-2878.	1.4	6
70	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 2016, 34, 1864-1871.	1.6	61
71	Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood, 2016, 128, 1671-1678.	1.4	179
72	Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and costâ€effective. Cancer Medicine, 2016, 5, 3059-3067.	2.8	18

#	Article	IF	Citations
73	Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. International Journal of Radiation Oncology Biology Physics, 2016, 96, 372-378.	0.8	15
74	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. Biology of Blood and Marrow Transplantation, 2016, 22, 520-527.	2.0	14
75	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
76	Phenotypic, genotypic, and functional characterization of normal and acute myeloid leukemia-derived marrow endothelial cells. Experimental Hematology, 2016, 44, 378-389.	0.4	13
77	Genetic engineering of platelets to neutralize circulating tumor cells. Journal of Controlled Release, 2016, 228, 38-47.	9.9	75
78	A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date. Blood, 2016, 128, 4049-4049.	1.4	5
79	Bone Marrow Mesenchymal Stem Cells from Acute Myelogenous Leukemia Patients Demonstrate Adipogenic Differentiation Propensity. Blood, 2016, 128, 5064-5064.	1.4	0
80	ABO Identical and Washed Transfusions Are Candidate Strategies to Reduce Early Mortality in Acute Promyelocytic Leukemia (APL). Blood, 2016, 128, 4011-4011.	1.4	0
81	Evolution to plasmablastic lymphoma evades CD19â€directed chimeric antigen receptor T cells. British Journal of Haematology, 2015, 171, 205-209.	2.5	83
82	Mixed lineage acute leukemia: navigating the heterogeneity. European Journal of Haematology, 2015, 95, 375-376.	2.2	0
83	Long-Lived Plasma Cells Are Contained within the CD19â^'CD38hiCD138+ Subset in Human Bone Marrow. Immunity, 2015, 43, 132-145.	14.3	415
84	Plerixafor: potential role in acute leukemia therapy. Expert Opinion on Orphan Drugs, 2015, 3, 467-475.	0.8	0
85	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biology of Blood and Marrow Transplantation, 2015, 21, 1830-1838.	2.0	12
86	Circulating endocannabinoids during hematopoietic stem cell transplantation: A pilot study. Neurobiology of Stress, 2015, 2, 44-50.	4.0	12
87	A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression. Blood, 2015, 126, 4266-4266.	1.4	1
88	Distinct Properties of Leukemia Stem Cells in Primary Refractory Acute Myeloid Leukemia. Blood, 2015, 126, 685-685.	1.4	1
89	Optimizing Effects of mTOR Inhibition in Acute Myelogenous Leukemia. Blood, 2015, 126, 4930-4930.	1.4	0
90	Modulation of Selectin-Mediated Adhesion of Flowing Lymphoma and Bone Marrow Cells by Immobilized SDF-1. International Journal of Molecular Sciences, 2014, 15, 15061-15072.	4.1	2

#	Article	IF	Citations
91	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
92	Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival. Blood, 2014, 124, 3984-3984.	1.4	1
93	Phase 1 study of the angiopoietin 1/2 neutralizing peptibody, trebananib, in acute myeloid leukemia.. Journal of Clinical Oncology, 2014, 32, 7082-7082.	1.6	4
94	Peri-Transplant Psychosocial Factors and Neutrophil Recovery following Hematopoietic Stem Cell Transplantation. PLoS ONE, 2014, 9, e99778.	2.5	25
95	Late Relapses Following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era. Blood, 2014, 124, 3999-3999.	1.4	0
96	Modulation of Interaction of Human Osteoprogenitor Cells with Hematopoietic Stem and Progenitor Cells. Blood, 2014, 124, 2933-2933.	1.4	0
97	A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leukemia Research, 2013, 37, 1622-1627.	0.8	24
98	A Phase 1 Trial of Eltrombopag in Patients Undergoing Stem Cell Transplantation after Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2013, 19, 1745-1752.	2.0	27
99	Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells. Journal of Biological Chemistry, 2013, 288, 33542-33558.	3.4	163
100	Stem Cell Enrichment with Selectin Receptors: Mimicking the pH Environment of Trauma. Sensors, 2013, 13, 12516-12526.	3.8	15
101	Surrogate end points for long-term outcomes in chronic myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 2103-2111.	1.3	5
102	Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients. Blood, 2013, 122, 2701-2701.	1.4	3
103	Phenotypic, Genotypic, and Functional Characterization Of AML-Derived Endothelial Cells. Blood, 2013, 122, 1411-1411.	1.4	9
104	Evolution Of Acute Myelogenous Leukemia Stem Cell Properties Following Treatment and Progression. Blood, 2013, 122, 883-883.	1.4	1
105	Targeting Myelogenous Leukemia Stem Cells: Role of the Circulation. Frontiers in Oncology, 2012, 2, 86.	2.8	8
106	Management of AML: Who do we really cure?. Leukemia Research, 2012, 36, 1475-1480.	0.8	13
107	Emergence of JAK2-mutant primary myelofibrosis in myelodysplastic syndrome: rare case report, literature review, and implications for clonal progression. Journal of Hematopathology, 2012, 5, 135-139.	0.4	0
108	Use of eltrombopag, a thrombopoietin receptor agonist, in postâ€transplantation thrombocytopenia. American Journal of Hematology, 2012, 87, 743-745.	4.1	43

#	Article	IF	Citations
109	Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Research, 2012, 9, 77-86.	0.7	59
110	Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells. Blood, 2012, 120, 206-206.	1.4	3
111	Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation. Blood, 2012, 120, 219-219.	1.4	2
112	Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia. Blood, 2012, 120, 3549-3549.	1.4	0
113	CML: Defining the efficacy of targeted therapy with the TARGET system. Leukemia Research, 2011, 35, 575-576.	0.8	0
114	Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation,. Blood, 2011, 118, 3295-3295.	1.4	2
115	Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Investigation, 2011, 29, 439-50.	1.3	8
116	Targeting Redox Homeostasis As a Means to Selectively Eradicate Primary Human Leukemia Cells,. Blood, 2011, 118, 3506-3506.	1.4	0
117	Biomolecular Surfaces for the Capture and Reprogramming of Circulating Tumor Cells. Journal of Bionic Engineering, 2009, 6, 311-317.	5.0	24
118	P-Selectinâ€“Coated Microtube for Enrichment of CD34+ Hematopoietic Stem and Progenitor Cells from Human Bone Marrow. Clinical Chemistry, 2008, 54, 77-85.	3.2	53
119	An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 2007, 110, 4427-4435.	1.4	357
120	Acute promyelocytic leukemiaâ€”mobile and infiltrative. Leukemia Research, 2007, 31, 5-7.	0.8	0
121	Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leukemia Research, 2007, 31, 1553-1563.	0.8	68
122	Investigating the Feasibility of Stem Cell Enrichment Mediated by Immobilized Selectins. Biotechnology Progress, 2007, 23, 1463-1472.	2.6	26
123	Improved Methodology for Detection of Mutations in the BCR-ABL Fusion Gene That Cause Resistance to the Tyrosine Kinase Inhibitor Imatinib.. Blood, 2006, 108, 2341-2341.	1.4	0
124	Acute myelogenous leukemiaâ€”microenvironment interactions: Role of endothelial cells and proteasome inhibition. Hematology, 2005, 10, 483-494.	1.5	34
125	The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood, 2005, 106, 1867-1874.	1.4	427
126	Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2004, 22, 1095-1102.	1.6	406

#	Article	IF	Citations
127	The Hematopoietic Stem Cell in Myelodysplasia. Stem Cells, 2004, 22, 590-599.	3.2	35
128	The CXCR4 Antagonist, AMD3100, Inhibits AML Transmigratory Activity but Does Not Alter Blast Proliferation or Survival.. Blood, 2004, 104, 2881-2881.	1.4	1
129	When what you have is not enough: optimizing cord blood transplantation in adults. Leukemia Research, 2003, 27, 197-199.	0.8	3
130	Flavonoid effects on normal and leukemic cells. Leukemia Research, 2003, 27, 517-527.	0.8	43
131	Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. Biology of Blood and Marrow Transplantation, 2002, 8, 662-665.	2.0	25
132	Response of Human CD34+Cells to CXC, CC, and CX3C Chemokines: Implications for Cell Migration and Activation. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 643-655.	1.8	31
133	MIP-1Î± and TGF-Î² Production in CD34+ Progenitorâ€“Stromal Cell Coculture Systems: Effects of Progenitor Isolation Method and Cellâ€“Cell Contact. Blood Cells, Molecules, and Diseases, 2000, 26, 261-275.	1.4	5
134	Analysis of Factors That Correlate With Mucositis in Recipients of Autologous and Allogeneic Stem-Cell Transplants. Journal of Clinical Oncology, 1999, 17, 2446-2446.	1.6	149
135	Effect of nitric oxide production and oxygen tension on progenitor preservation in ex vivo culture. Experimental Hematology, 1999, 27, 441-450.	0.4	53
136	Expression of Interleukin-7 Receptor by Lineage-Negative Human Bone Marrow Progenitors With Enhanced Lymphoid Proliferative Potential and B-Lineage Differentiation Capacity. Blood, 1997, 89, 929-940.	1.4	86
137	Hypereosinophilic syndromes: an update. International Journal of Clinical and Laboratory Research, 1996, 26, 5-10.	1.0	0
138	Hypereosinophilic syndromes: an update. International Journal of Clinical and Laboratory Research, 1996, 26, 5-7.	1.0	0
139	Integrins and Adhesive Receptors in Normal and Leukemic CD34+ Progenitor Cells: Potential Regulatory Checkpoints for Cellular Traffic. Leukemia and Lymphoma, 1994, 14, 19-28.	1.3	59
140	Hypereosinophilic syndromes: an update. International Journal of Clinical and Laboratory Research, 1992, 22, 5-10.	1.0	2
141	Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity. Journal of Cellular Biochemistry, 1991, 45, 381-390.	2.6	29
142	Treatment patterns in low-grade non-Hodgkin's lymphomas: A single institution study. Medical and Pediatric Oncology, 1991, 19, 1-7.	1.0	1
143	Effect of hydrocortisone and interleukins 1 and 2 on eosinophil progenitors in hypereosinophilic states. International Journal of Cell Cloning, 1988, 6, 404-416.	1.6	1